Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA

Bayer Stock Up On Growth View Starting FY26, Despite Q4 Loss, Cautious FY25

Shares of Bayer AG were gaining around 6 percent in the German trading after the pharmaceutical and life sciences major Wednesday said it expects improved performance from 2026 onwards, despite reporting a slip to loss in its fourth quarter. The company also projects weak core earnings and nearly flat sales for fiscal 2025.

RTTNews | 1 day ago

Bayer Stock Slips On Q3 Loss, Cautious Outlook

Shares of Bayer AG were losing around 11 percent in the morning trading on Germany's XETRA after the pharmaceutical and life sciences major reported Tuesday loss in its third quarter and weak adjusted EBITDA, amid nearly flat sales. The net loss, however, was narrower than last year, while EBIT loss widened. Further, the company trimmed its fiscal 2024 adjusted EBITDA forecast for the group...

RTTNews | 114 days ago

Bayer Stock Climbs On US Legal Win In Roundup Cancer Claims

Shares of Bayer AG were climbing around 11 percent in German trading after the pharmaceutical and life sciences major announced a favorable ruling in the United States in the lawsuit over cancer claims against its Roundup weed killer. In a statement, the company noted that the Third Circuit Court of Appeals issued its favorable ruling in Schaffner v. Monsanto...

RTTNews | 201 days ago

Bayer Q4 Profit Surges, Warns On FY24; Says Break-up Not Now

German pharmaceutical and biotechnology major Bayer AG reported Tuesday a surge in its fourth-quarter net profit benefited by weak expenses. Meanwhile, sales were hurt by lower Pharmaceuticals sales, despite growth in Crop Science and consumer Health segments. Further, the company trimmed its dividend, and said it sees lower adjusted earnings and nearly flat sales in fiscal 2024 on a currency-adju

RTTNews | 366 days ago

Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Friday that Mirena (52mg LNG IUS), its long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception. This is the longest contraceptive duration of use for any hormonal intrauterine system.

RTTNews | 874 days ago

European Shares Mostly Higher Ahead Of ECB Meeting

European shares traded higher on Thursday as trade worries eased, and investors looked ahead to the European Central Bank's interest-rate decision and President Christine Lagarde's press conference later in the day for direction.

RTTNews | 5h 16min ago

Asian Shares Climb Led By China And Hong Kong

Asian stocks advanced on Thursday after U.S. President Donald exempted automakers from newly imposed tariffs on Mexico and Canada for one month, raising hopes for negotiations.

RTTNews | 5h 39min ago

Commodity Currencies Rise Amid Risk-on Mood

The commodity currencies such as Australia, the New Zealand and the Canadian dollars strengthened against their major currencies in the Asian session on Thursday amid risk appetite, as traders react positively to news that the Trump administration announced a one-month delay on tariffs affecting cars entering the U.S. from Canada and Mexico, raising hopes for negotiations.

RTTNews | 6h 19min ago

EURUSD	1.07986	GBPUSD	1.2902	AUDUSD	0.63389
USDJPY	147.884	USDCAD	1.43404	USDCHF	0.88765

Advertisement

Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA